Onc Now: Episode 24: What Will the Next Decade of HER2-Targeted Therapy Look Like?

In this episode of Onc Now, host Jonathan Sackier welcomes Komal Jhaveri, Breast Medical Oncologist and clinical investigator at Memorial Sloan Kettering Cancer Center, New York, USA. Known for her trailblazing work in HER2-positive, HER2-low, and hormone receptor-positive breast cancers, Komal Jhaveri discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field.     Timestamps  00:00 – Introduction  02:50 – What initially drew Komal into oncology   04:45 – The future of breast cancer care  06:13 – Possibility of personalised treatments for patients  07:40 – Antibody-drug conjugates  09:30 – How we define HER2 status  14:40 – HER2-low disease  17:40 – Targeted therapy combinations  20:54 – Endocrine resistance  23:18 – The realities of implementing new therapies   28:40 – Promising initiatives on the horizon  31:30 – Komal's key takeaways  

There are no comments yet.

Please log in to write the first comment.